| Company Name: |
BOC Sciences |
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
Laniquidar manufacturers
- Laniquidar
-
- $4640.00
-
2026-04-21
- CAS:197509-46-9
- Purity:
- Supply Ability: 10g
|
| | Laniquidar Basic information |
| Product Name: | Laniquidar | | Synonyms: | LANIQUIDAR;R101933;R 101933;R-101933;R 101933;R101933;R-101933;5H-Imidazo[2,1-b][3]benzazepine-3-carboxylic acid, 6,11-dihydro-11-[1-[2-[4-(2-quinolinylmethoxy)phenyl]ethyl]-4-piperidinylidene]-, methyl ester;Methyl 11-(1-(4-(quinolin-2-ylmethoxy)phenethyl)piperidin-4-ylidene)-6,11-dihydro-5H-benzo[d]imidazo[1,2-a]azepine-3-carboxylate | | CAS: | 197509-46-9 | | MF: | C37H36N4O3 | | MW: | 584.71 | | EINECS: | | | Product Categories: | | | Mol File: | 197509-46-9.mol |  |
| | Laniquidar Chemical Properties |
| Boiling point | 793.1±70.0 °C(Predicted) | | density | 1.24±0.1 g/cm3(Predicted) | | pka | 8.46±0.20(Predicted) |
| | Laniquidar Usage And Synthesis |
| Uses | Laniquidar (R101933) is a noncompetitive, third generation P-glycoprotein (P-gp) inhibitor with an IC50 of 0.51 μM. Laniquidar can be used for modulating multidrug resistance transporters[1]. Laniquidar can also be used for studying acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)[2]. Laniquidar has limited oral bioavailability[3]. | | References | [1] Luurtsema G, et al. Evaluation of [11C]laniquidar as a tracer of P-glycoprotein: radiosynthesis and biodistribution in rats. Nucl Med Biol. 2009 Aug;36(6):643-9. DOI:10.1016/j.nucmedbio.2009.03.004
[2] Ross DD. Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004 Dec;17(4):641-51. DOI:10.1016/j.beha.2004.08.014
[3] Fox E, et al. Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor. Expert Rev Anticancer Ther. 2007 Apr;7(4):447-59. DOI:10.1586/14737140.7.4.447 |
| | Laniquidar Preparation Products And Raw materials |
|